PatientsVille.com Logo


Crixivan Medical Research Studies

Up-to-date List of Crixivan Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Crixivan Medical Research Studies

Rank Status Study
1 Unknown  External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Condition: Cancer
Interventions: Drug: indinavir sulfate;   Drug: ritonavir;   Radiation: radiation therapy
Outcome Measures: Time to treatment failure in the brain (TTF) as determined by the radiological response rate;   Overall survival (OS);   Radiological volumetric response to treatment;   Local intracranial disease progression at 4 months;   Progression-free survival at 6 months;   Improvement of symptoms;   Time to symptom relapse or symptom progression;   Duration of use of steroids;   Duration of use of anticonvulsive drugs
2 Unknown  A Prospective Cohort of Children With HIV Infection
Condition: HIV Infections
Interventions: Drug: Zidovudine, Stavudine, Didanosine, Lamivudine;   Drug: Nevirapine, Efavirenz;   Drug: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir
Outcome Measure: 1. To collect clinical and immunologic data of children treated with HAART 2. To collect clinical outcome data on children with HIV infection 3. To provide the best possible care to children with HIV infection
3 Recruiting IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents
Conditions: ADHD;   HIV
Outcome Measure: Estimation of steady-state oral clearance (Cl/F) for each psychiatric study medication is the primary outcome.
4 Recruiting Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Interventions: Drug: ATV;   Drug: DRV;   Drug: Cobicistat;   Drug: BR
Outcome Measures: Plasma pharmacokinetics (PK) parameters of ATV and DRV (as measured by AUCtau) at Day 10;   Incidence of treatment-emergent adverse events and laboratory abnormalities;   PK parameters of ATV and DRV (as measured by Ctau, Cmax, CL/F) and cobicistat (as measured by AUCtau, Cmax, Ctau, CL/F, and Vz/F);   Percentage of participants with plasma HIV-1 RNA < 50 copies/mL;   The time to pure virologic failure;   Change from baseline in log10 HIV-1 RNA (copies/mL);   Change from baseline in CD4+ cell count (cells/µL);   Acceptability (assessed by adherence) and palatability of cobicistat;   Change from baseline in CD4 percentage;   Change from baseline in CD4 percentage in participants < 5 years old

These studies may lead to new treatments and are adding insight into Crixivan etiology and treatment.

A major focus of Crixivan research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Crixivan